Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729774 | 0.91 | ALDH1A1 (0.35) | MGLLMAPTALDH1A1HPGDTSHR | |
| SCHEMBL22755233 | 0.88 | MGLL (0.33) | MGLL | |
| SCHEMBL22729616 | 0.87 | MGLL (0.44) | MGLLMAPTTP53SMN1; SMN2 | |
| SCHEMBL29839356 | 0.87 | MGLL (0.44) | MGLLMAPTTP53SMN1; SMN2 | |
| SCHEMBL22729739 | 0.87 | MGLL (0.41) | MGLLMAPTTP53SLC6A9 | |
| SCHEMBL23116381 | 0.84 | MGLL (0.39) | MGLLMAPTTP53ALDH1A1HPGD | |
| SCHEMBL29839276 | 0.84 | MGLL (0.39) | MGLLMAPTTP53ALDH1A1HPGD | |
| SCHEMBL22729757 | 0.84 | GRIN2B (0.36) | MGLL | |
| SCHEMBL29839330 | 0.84 | GRIN2B (0.36) | MGLL | |
| SCHEMBL23116391 | 0.84 | MGLL (0.41) | MGLLMAPTALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | MGLL 92/4885MAPT 356/4885TP53 3839/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | MGLL 91/4885MAPT 364/4885TP53 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.